Trial Title:
Olaparib Maintenance Therapy in Metastatic Breast Cancer
NCT ID:
NCT05629429
Condition:
Metastatic Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Olaparib
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Olaparib
Description:
Olaparib 300mg BID PO
Arm group label:
Arm 1: olaparib treatment
Intervention type:
Drug
Intervention name:
Chemotherapy drug
Description:
Continue platinum based chemotherapy
Arm group label:
Arm2: continuation of the chemotherapy
Summary:
Olaparib, a PARP inhibitor, is proven as an effective therapy for germline
BRCA1/2-mutated breast cancer; however, the therapeutic efficacy for somatic mutation in
BRCA1/2 or genes of homologous recombination DNA repair is unclear. Maintenance of
Oalaprib can delay the disease progression in patients with BRCA1/2 mutated advanced
ovarian cancer after treatment with platinum based chemotherapy. The investigators design
a phase 2 study to evaluate the efficacy of maintenance of Olaparib in patients with
metastatic breast cancer. The investigators enroll patients with metastatic ER(+)Her2(-)
or triple-negative breast cancer. Patients who are chemotherapy-naïve or prior 1-line
chemotherapy are eligible for screening. All eligible patients will receive 4 cycles of
platinum based chemotherapy. Gene test will be performed on their breast tumor. If
patients have mutation of HR genes and at least stable disease after platinum based
chemotherapy, they will be randomized to treatment arm (Olaparib maintenance) or control
arm (continuation of chemotherapy). The primary end-point is progression-free survival,
and the secondary end-point is to assess the response rate, overall survival and quality
of life.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Patients must have a life expectancy ≥ 16 weeks.
2. Provision of informed consent prior to any study specific procedures
3. 20 years of age or older; gender includes female and male
4. ECOG 0-1
5. Patients should be diagnosed as metastatic breast cancer ER(+)Her2(-) or TNBC,
diagnosis could be by local hospital
6. HER2 negative [IHC 0, 1+ or IHC 2+ with corresponding ISH non-amplified of ratio
less than 2.0 or ISH nonamplified ratio less than 2.0] as per ASCO-CAP HER2
guideline recommendations 2013 (ASCO-CAP).
7. At least one lesion, not previously irradiated, that can be accurately measured at
baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have
short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging
(MRI)
8. Postmenopausal or evidence of non-childbearing status for women of childbearing
potential: negative urine or serum pregnancy test within 28 days of study treatment
and confirmed prior to treatment on day 1. Postmenopausal is defined at least one of
the followings: (a) Amenorrheic for 1 year or more following cessation of exogenous
hormonal treatments; (b) Luteinizing hormone (LH) and Follicle stimulating hormone
(FSH) levels in the post menopausal range for women under 50; (c) radiation- induced
oophorectomy with last menses >1 year ago; (d) chemotherapy-induced menopause with
>1 year interval since last menses; (f) surgical sterilisation (bilateral
oophorectomy or hysterectomy)
9. Male patients must use a condom during treatment and for 3 months after the last
dose of olaparib when having sexual intercourse with a pregnant woman or with a
woman of childbearing potential. Female partners of male patients should also use a
highly effective form of contraception ([see appendix H for acceptable methods]) if
they are of childbearing potential
10. No more than previous 0-1 line of chemotherapy after metastasis confirmed
11. For ER(+) breast cancer, patients should fail at least 1-line of hormone therapy
(either in adjuvant setting or in metastatic cancer) before entering this study
12. Patients should undergo 4-cycles of platinum-based chemotherapy and have a CR, PS or
SD prior to randomisation.
13. At least one measurable lesion that can be accurately assessed at baseline by
computed tomography (CT) (magnetic resonance imaging [MRI] where CT is
contraindicated) and is suitable for repeated assessment as per RECIST 1.1.
14. Patients must have normal organ and bone marrow function measured within 28 days
prior to randomisation as defined below:
1. Haemoglobin (Hb) ≥10.0 g/dL
2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
3. Platelet count ≥100 x 109/L
4. Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) unless the
patient has documented Gilbert's Syndrome
5. Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase
(SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase
(SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are
present in which case they must be ≤ 5x ULN
6. Patients must have creatinine clearance (CrCl) of ≥51 mL/min estimated or
measured using standard methodology at the investigating centre (i.e.
Cockcroft-
Gault, MDRD, CK-EPI, EDTA or 24 hr urine):
- Exclusion Criteria:
- Patients should not enter the study if any of the following exclusion criteria are
fulfilled:
1. Cytotoxic chemotherapy, hormonal or non hormonal targeted therapy within 21 days of
Cycle 1 Day 1 is not permitted. Palliative radiotherapy must have been completed 21
or more days before Cycle 1 Day 1. The patient can receive a stable dose of
bisphosphonates or denosumab for bone metastases, before and during the study as
long as these were started at least 5 days prior to study treatment.
2. More than 2 prior lines of cytotoxic chemotherapy for metastatic disease.
1. Prior treatments with hormonal therapy and non hormonal targeted therapy are
allowed and not counted as a prior line of cytotoxic chemotherapy.
2. For the purposes of this protocol, the combination of "an aromatase inhibitor
and everolimus" or "a hormonal therapy and CDK4/6 inhibitor" is not considered
cytotoxic chemotherapy.
3. Treatment with biologics will not be considered as prior line of therapy.
4. Patients receiving any systemic chemotherapy or radiotherapy (except for
palliative reasons) within 3 weeks prior to study treatment
3. Previous treatment with a PARP inhibitor (including olaparib)
4. The minimum washout period for immune checkpoint blockade therapy shall be 21 days.
5. Patients with MDS/AML or with features suggestive of MDS/AML.
6. Patients with second primary cancer, EXCEPTIONS: adequately treated non melanoma
skin cancer, curatively treated in-situ cancer of the cervix, Ductal Carcinoma in
Situ (DCIS), stage 1 grade 1 endometrial carcinoma, or other solid tumours
curatively treated with no evidence of disease for ≥ 5 years prior to study entry
(including lymphomas [without bone marrow involvement]).
7. Mean resting corrected QTc interval using the Fridericia formula (QTcF) >470
msec/female patients and >450 msec for male patients (as calculated per
institutional standards) obtained from 3 ECGs performed 2-5 minutes apart at study
entry, or congenital long QT syndrome.
8. Any of the following cardiac diseases currently or within the last 6 months
1. Unstable angina pectoris
2. Congestive heart failure ≥ Class 2 as defined by the New York Heart Association
3. Acute myocardial infarction
4. Conduction abnormality not controlled with pacemaker or medication (patients
with a conduction abnormality controlled with pacemaker or medication at the
time of screening are eligible)
5. Significant ventricular or supraventricular arrhythmias (patients with chronic
rate- controlled atrial fibrillation in the absence of other cardiac
abnormalities are eligible)
9. Concomitant use of known strong cytochrome P (CYP) 3A inhibitors (eg. itraconazole,
telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or
cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate
CYP3A inhibitors (eg.
ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required
washout period prior to starting study treatment is 2 weeks.
Patient has had prescription or non-prescription drugs or other products known to be
sensitive CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or
to be moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued
2 weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks
after the last dose of study drug. Patients should stop using herbal medications 7
days prior to first dose of study treatment.
10. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin,
rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or
moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout
period prior to starting study treatment is 5 weeks for enzalutamide or
phenobarbital and 3 weeks for other agents.
11. Persistent toxicities (≥ CTCAE grade 2) caused by previous cancer therapy, excluding
alopecia.
12. Major surgery within 2 weeks of starting study treatment: patients must have
recovered from any effects of any major surgery.
13. Immunocompromised patients, eg, patients who are known to be serologically positive
for human immunodeficiency virus (HIV).
14. Patients considered a poor medical risk due to a serious, uncontrolled medical
disorder, non-malignant systemic disease or active, uncontrolled infection.
a. Examples include, but are not limited to, uncontrolled ventricular arrhythmia,
recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder,
unstable spinal cord compression, superior vena cava syndrome, extensive
interstitial bilateral lung disease on High Resolution CT scan or any psychiatric
disorder that prohibits obtaining informed consent, and any other medical condition
that, in the opinion of the Investigator, places the patient at unacceptable risk of
toxicity.
15. Patients with symptomatic uncontrolled brain metastases.
1. A scan to confirm the absence of brain metastases is not required. The patient
can receive a stable dose of corticosteroids before and during the study as
long as these were started at least 4 weeks prior to treatment. Patients with
spinal cord compression unless considered to have received definitive treatment
for this and evidence of clinically stable disease (SD) for 28 days.
2. Patients with a history of treated central nervous system (CNS) metastases are
eligible, provided they meet all of the following criteria: Disease outside the
CNS is present. No clinical evidence of progression since completion of
CNS-directed therapy. Minimum of 3 weeks between completion of radiotherapy and
Cycle 1 Day 1 and recovery from significant (Grade ≥3) acute toxicity with no
ongoing requirement for >10 mg of prednisone per day or an equivalent dose of
other corticosteroid. If on corticosteroids, the patient should be receiving a
stable dose of corticosteroids, started at least 4 weeks prior to treatment.
16. Patients unable to swallow orally administered medication and patients with
gastrointestinal disorders likely to interfere with absorption of the study
medication.
17. Patients with a known hypersensitivity to olaparib or any of the excipients of the
products.
18. Pregnant or breast feeding women.
19. Patients with HBV infection and uncontrolled hepatitis are not eligible. If patients
are HBV carriers (HBsAg-positive without 2.5x elevation of AST/ALT), these patients
can enter study if they have baseline HBV-DNA level assessed during screening,
receive prophylactic medication and regularly monitored by GI doctor. Patients
positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain
reaction is negative for HCV RNA.
20. Previous allogenic bone marrow transplant or double umbilical cord blood
transplantation (dUCBT)
21. Whole blood transfusions in the last 120 days prior to entry to the study (packed
red blood cells and platelet transfusions are acceptable, for timing refer to
inclusion criteria no.7
Gender:
All
Minimum age:
20 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Taipei Veterans General Hospital
Address:
City:
Taipei City
Country:
Taiwan
Status:
Not yet recruiting
Contact:
Last name:
Chi-Cheng Huang
Email:
chishenh74@gmail.com
Investigator:
Last name:
Ta-Chung Chao
Email:
Principal Investigator
Facility:
Name:
National Taiwan University Hospital
Address:
City:
Taipei
Zip:
100
Country:
Taiwan
Status:
Recruiting
Contact:
Last name:
Po-Han Lin
Phone:
0223123456
Phone ext:
71928
Email:
pohanlin01@gmail.com
Facility:
Name:
National Taiwan University Hospital Yunlin branch
Address:
City:
Yuanlin
Country:
Taiwan
Status:
Not yet recruiting
Contact:
Last name:
Hsing-wu Chen
Email:
hsingwuc@gmail.com
Investigator:
Last name:
Hsing-wu Chen
Email:
Principal Investigator
Start date:
February 7, 2023
Completion date:
December 31, 2025
Lead sponsor:
Agency:
National Taiwan University Hospital
Agency class:
Other
Collaborator:
Agency:
AstraZeneca
Agency class:
Industry
Source:
National Taiwan University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05629429
